According to Rao et al., luteolin overcomes MDR in breast cancer mitoxantrone resistant cells through increased apoptosis, DNA damage, activation of ATR/Chk2/p53 signaling pathways, inhibition of NF-κB signaling pathway and depletion of anti-apoptotic proteins [189]. This evidence concerns the gene NFKB1 and breast carcinoma.